Ultragenyx Pharmaceutical RARE Royalty — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's royalty — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's royalty — revenue?
- Ultragenyx Pharmaceutical (RARE) reported royalty — revenue of $47M in Q1 2026.
- How has Ultragenyx Pharmaceutical's royalty — revenue changed year-over-year?
- Ultragenyx Pharmaceutical's royalty — revenue decreased by 2.1% year-over-year, from $48M to $47M.
- What is the long-term trend for Ultragenyx Pharmaceutical's royalty — revenue?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's royalty — revenue has grown at a 102.9% compound annual growth rate (CAGR), from $17.95M to $304.22M.
- What does royalty — revenue mean?
- This metric represents the total gross revenue recognized from royalty-based licensing agreements or intellectual property partnerships within a specific business segment. It reflects the inflow of economic benefits derived from the commercialization of products by third-party licensees, excluding any pass-through taxes. Monitoring this figure helps investors assess the scalability and recurring nature of high-margin royalty streams independent of direct product manufacturing costs.